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Abstract
Background: According to the literature and our experience, the most common sites of non-small cell lung cancer
(NSCLC) metastases include the brain, bone, liver, adrenal glands, contralateral lung and distant lymph nodes.
Metastases to other organs are relatively rare. There have been numerous case reports and a few small case series
of uncommon metastases derived from NSCLC.
Methods: We defined all organs except the common metastatic sites mentioned above as uncommon sites of
metastasis. Patients with uncommon metastases among 2,872 consecutive NSCLC patients with stage IV disease
at the Guangdong Lung Cancer Institute (GLCI) from 2006 to 2012 were included in this study. The diagnosis of
uncommon metastases was based on pathology or imaging studies.
Results: Uncommon metastases were diagnosed in 193 cases at anatomical sites such as the soft tissue, kidney,
pancreas, spleen, peritoneum, intestine, bone marrow, eye, ovary, thyroid, heart, breast, tonsil and nasal cavity.
Uncommon metastases were identified as independent poor prognostic factors through a multivariate analysis
with a HR (hazard ratio) of 1.29 [95 % confidence interval (CI) 1.09–1.52, P < 0.01]. Those patients who received
systemic therapy plus local treatment had a better survival rate than did those who received systemic therapy
only (P < 0.01); all patients received best supportive care.
Conclusions: Metastases to the above mentioned sites are infrequent. The presentation of uncommon
metastases tends to indicate a poor outcome, and selected patients may benefit from local treatment.
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Background
Approximately 50 % of lung cancer cases are metastatic at
diagnosis [1]. The major sites of non-small cell lung cancer
(NSCLC) metastases include the brain (47 %), bone (36 %),
liver (22 %), adrenal glands (15 %), thoracic cavity (11 %)
and distant lymph nodes (10 %) [2, 3]. All other organs me-
tastases are very rare and general less than 5 %. So we
could define them as uncommon metastases. To our
knowledge only some case reports were presented and
there were limit information available on uncommon me-
tastases of NSCLC in the literatures [4–12]. Thus, no sys-
tematic body of knowledge on the epidemiology, diagnosis,
or treatment of such metastases is available. Misdiagnosis
is common because it is difficult to distinguish uncommon
metastases from primary malignancies. The treatment is
often controversy when uncommon metastasis is solitary.
Local therapy is always considered in such settings, al-
though uncommon metastases are grouped as M1b, stage
IV based on lung cancer staging system [13]. Herein, we
review all cases with uncommon metastases identified at
the Guangdong Lung Cancer Institute (GLCI) between
2006 and 2012, and we report the epidemiological char-
acteristics, diagnosis, treatment and prognosis of the
patients. Our purpose was to evaluate survival out-
comes, to define predictors of survival, and to provide
information to clinicians on how to treat uncommon
metastases derived from NSCLC.
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Patients and methods
The definition of uncommon metastases is metastatic
sites exclusive of the brain, bone, liver, adrenal glands,
thoracic cavity and distant lymph nodes. All patients di-
agnosed with uncommon metastases from 2,872 con-
secutive NSCLC patients with stage IV disease, at the
initial presentation or during follow-up at the GLCI
from 2006 to 2012 were included in this study, which
was approved by the ethics committee of Guangdong
General Hospital. All patients provided written informed
consent for participation were included in the study.
Otherwise they were not included. The diagnosis of soft
tissue metastases was based on pathology, imaging re-
sults, or clinical manifestations. Metastases located in
the skeletal muscle/subcutaneous/cutaneous tissues were
included,however, those in important lymphatic drainage
areas (e.g., the groin and axilla) were excluded unless
they were pathologically diagnosed as soft tissue metas-
tases. Metastases located in lymphatic regions are more
likely to be metastases in lymph nodes rather than soft
tissue. The diagnosis of other uncommon metastatic
sites (e.g., the kidneys and pancreas) depended mostly
on imaging studies, including computed tomography
(CT), magnetic resonance imaging (MRI), and positron
emission tomography/computed tomography (PET/CT).
The diagnosis of metastases to those organs was con-
firmed by two independent radiologists and a physician.
We wonder whether patients with uncommon metasta-
ses diagnosed at different time would experience different
prognoses. Thus, we defined two clinical situations: syn-
chronous and metachronous diagnoses. Synchronous me-
tastases were defined as clinically and/or radiologically
uncommon metastases identified at the time of lung can-
cer diagnosis. Metachronous metastases were defined as
uncommon metastases diagnosed after the initial diagno-
sis of primary lung cancer.
Chi-square or Fisher’s exact tests were used to compare
qualitative data. Nonparametric tests were used to analyze
the quantitative data. Overall survival (OS) was estimated
using the Kaplan-Meier method, and the difference in sur-
vival between the subgroups was compared using a log-
rank test. To estimate the risk of OS in the cohort of
2,872 patients, the group (common or uncommon metas-
tasis), age, gender, cigarette smoking history, ECOG PS,
pathology and systematic treatment or not were used as
covariates in a multivariate Cox regression model. All ana-
lyses were performed using the SPSS 17.0 software pro-
gram. All statistical tests were two-sided, and P < 0.05 was
deemed to indicate statistical significance.
Results
Overall, 193 cases (6.7 %) were identified as having un-
common metastases among 2,872 consecutive NSCLC
cases from 2006 to 2012. Sixteen cases had more than
one uncommon metastatic organ.
Clinical features
The clinical characteristics of cases with common and
uncommon metastases are shown in Table 1. Compared
with the common metastasis group, the patients in the
uncommon metastasis group were more likely have
metachronous metastases (P < 0.01) and were more
likely to be male (P = 0.02). Other clinical factors such as
age, smoking status, ECOG PS, histology and treatment
were balanced between the two groups.
The most uncommon metastatic sites, in decreasing
order of frequency, were the soft tissue, kidney, periton-
eum, spleen, pancreas, intestine, bone marrow, eye, ovary,







n % n %
Age (years) 0.36
Median (range) 58 (20–85) 59 (17–89)
Gender 0.02
Male 137 71.0 1673 62.4
Female 56 29.0 1006 37.6
Smoking status 0.08
Smoker 99 51.3 1197 44.7
Never smoker 94 48.7 1482 55.3
ECOG PS 0.96
<2 175 90.7 2423 90.4
=2 12 6.2 178 6.6
>2 6 3.1 78 2.9
Diagnosis time <0.01
At disease course 82 43.0 415 15.5
At intial 111 57.0 2264 84.5
Histology 0.41
Adenocarcinoma 151 78.2 2178 81.3
Squamous carcinoma 26 13.5 339 12.7
Othersa 16 9.0 162 6.0
Treatment
>2 lines 35 18.1 410 15.3 0.49
≤2 lines 122 63.2 1795 67.0
BSC 36 18.7 474 17.7
TKIs or not 0.06
Yes 56 29.0 959 35.8
No 137 71.0 1720 64.2
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status
aOther types of histology except adenocarcinomas and squamous carcinoma
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thyroid, heart, breast, nasal cavity and tonsil. Figure 1
shows the frequency of metastasis at each uncommon site.
In total, 111 cases were diagnosed with synchronous
metastases and 82 with metachronous metastases. In the
latter group, the median duration between the initial
diagnosis of lung cancer and the identification of un-
common metastases was 9.5 months. There were no sig-
nificant differences in the other patient characteristics,
including age, gender, smoking status, ECOG PS, hist-
ology and single-lesion or multiple-lesion metastases,
between the two groups.
Diagnosis and treatment
There were 84 uncommon metastatic sites diagnosed by
pathology, 41 by PET/CT, 68 by CT, 14 by clinical signs, 4
by MRI. In the 84 uncommon metastases diagnosed by
pathology, 71 patients were diagnosed with adenocarcin-
oma, 13 with squamous carcinoma, 2 with adenosqua-
mous carcinoma, and 1 with squamous cell carcinoma
combined with giant cell carcinoma. The histological fea-
tures of the metastases were consistent with those of the
primary tumors. Overall, 64 of the 84 patients had soft tis-
sue metastases, 9 had peritoneal metastases, 3 had intes-
tinal metastases, 1 had bone marrow metastases, and 1
each had kidney, pancreas, ovary, heart, breast, nasal cav-
ity, and tonsil metastases.
In uncommon metastasis group, there were 157 pa-
tients received systematic treatment and the other 36 pa-
tients just received best supportive care (BSC) because
of poor PS or poor financial condition. In common me-
tastasis group, there were 2205 patients received system-
atic treatment and the other 474 patients just received
BSC. The detailed treatment of both groups was shown
in table 1.
After the diagnosis of uncommon metastases, 112 cases
received systemic treatment without local treatment, 19
received systemic treatment plus local treatment, and the
remaining patients received only BSC. Twelve and seven
cases, respectively, in the synchronous and metachronous
metastasis groups received local treatment. The systemic
treatments included chemotherapy and targeted therapy.
The local treatments included surgical extirpation, stereo-
tactic body radiation therapy, and radiofrequency ablation.
Survival analysis
A total of 151 cases with uncommon metastases died of
lung cancer. The median OS (mOS) from the initial diag-
nosis of lung cancer to death was 13.0 months (95 % CI:
10.1–15.9 months) in 193 cases. The mOS from the diag-
nosis of uncommon metastases to death was 5.9 months
(95 % CI: 4.6–7.0 months) in 193 cases.
As seen in Fig. 2, the mOS after the diagnosis of lung
cancer was significantly shorter in patients with un-
common metastases versus common metastases (mOS
13.0 months [95 % CI: 10.1–15.9] vs. 18.3 months
[17.4–19.2], P < 0.01). The 1-year survival rates were
53.9 and 66.0 %, respectively. Figure 3 shows the mOS
after the diagnosis of uncommon metastases.
There was no significant difference in survival time
after the diagnosis of uncommon metastases between
the metachronous and synchronous metastasis groups
(mOS 5.5 months [95 % CI: 3.4–7.6] vs. 6.0 months
[95 % CI: 4.0–8.0], P = 0.91).
OS was significantly longer among patients who re-
ceived systemic therapy plus local treatment compared
to those who received systemic therapy alone, and
those who received BSC (mOS: 12.5 months [95 % CI:
4.5–20.5] vs. 7.4 months [95 % CI: 5.2–9.6] vs.
3.4 months [95 % CI: 2.7–4.1]; P < 0.01) (Fig. 4).
Fig. 1 The frequency of uncommon metastases
Fig. 2 Survival from the time of lung cancer diagnosis in cases with
common and uncommon metastases
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Multivariate stepwise Cox regression analysis
Four of the seven variables mentioned in the “patients
and methods” section were found to be independent
poor prognostic factors through a multivariate stepwise
Cox regression analysis, as shown in Table 2. Uncom-
mon metastases were associated with a hazard ratio
(HR) of 1.29, following PS (HR = 2.15), no systematic
treatment (HR = 2.06) and female (HR = 1.30).
Discussion
Numerous case reports and a few studies (with small
sample sizes) that have evaluated uncommon metastases
from lung carcinomas. Unfortunately, these reports have
only marginally improved our understanding of the clin-
ical features and outcomes of patients with the disease.
Therefore, we reviewed the medical records of patients
with NSCLC treated at the GLCI from 2006 to 2012 and
reported the cases with uncommon metastases herein.
To our knowledge, this is the largest case series of un-
common metastases from NSCLC.
As shown in Table 1, there were no significant differ-
ences in clinical characteristics at baseline between the
common and uncommon groups except gender and diag-
nosis time. The predominant gender was male in cases
with uncommon metastasis (P = 0.02), as has been noted
in other reports [14]. Uncommon metastases were more
likely to be diagnosed later in the disease course (P < 0.01).
The reason why uncommon metastases most often occurs
at disease course may be that the uncommon metastatic
organs couldn’t provide suitable microenvironment to sup-
port tumor cells’ survival. It will take time for tumor cells
to evolve to adapt the hostile microenvironment. The or-
gans to which lung cancer uncommonly metastasizes are
also usually unaffected in patients with other cancers. The
reasons why these organs are rarely involved in cancers in-
cluding NSCLC are as follows. K. A. Kovács, et al. [15] pro-
posed that the skin only shared 5 % of the cardiac output
of blood at resting condition, and was a very active part of
immune system. The rarity of skeletal muscle metastases
has been attributed to changes in pH, metabolite accumu-
lation, variable blood flow, and variation in tissue pressure
[16–18]. The spleen has always been considered “poor soil”
for tumor growth, probably because of the high population
of immune cells therein and the role played by that organ
in “immune surveillance” [19]. Further, anti-angiogenesis
factors produced by the spleen may explain the rarity of
splenic metastases.
Uncommon metastases from lung tumors are included
rarely in prognostic analyses. We speculated that pa-
tients with uncommon metastases would be more likely
Fig. 3 Survival from the time of the uncommon metastasis diagnosis.
*: uncommon metastases except kidney/soft tissue/pancreas/spleen/
peritoneum
Fig. 4 Survival from the time of the uncommon metastasis diagnosis
in patients who received different treatments. Abbreviations: S,
systemic treatment; L, local treatment; B, best supportive care
Table 2 Independent prognostic factors from multivariate
analysis between common and uncommon metastasis groups
Harzard ratio 95 % CI P
PS
0–1 1.00 - -
2 1.63 1.38–1.93 <0.01
>2 2.13 1.68–2.69 <0.01
Systematic treatment
Yes 1.00 - -
No 2.06 1.82–2.32 <0.01
Sex
Female 1.00 - -
Male 1.30 1.18–1.42 <0.01
Groups
Common metastasis 1.00 - -
Uncommon metastasis 1.29 1.09–1.52 <0.01
Abbreviations: 95 % CI 95 % confidential interval, PS performance status
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to have a poor outcome, according to previous case re-
ports. A few articles have suggested that certain uncom-
mon metastases, such as subcutaneous metastases [20],
are associated with a shorter survival time. According to
our multivariate analysis data, uncommon metastases in-
dependently predict a poorer survival on multivariate
analysis (HR 1.29, P < 0.01). The fact that tumor cells
could survive in hostile microenvironment provided by
the uncommon organ (s) is evidence that such cells are
particularly aggressive and invasive, which may contrib-
ute to the poor prognosis of these patients.
Uncommon metastases often develop late in the
course of disease but also may present at initial diagno-
sis. We explored whether synchronous and metachro-
nous metastases are different diseases or simply reflect
different courses of the same disease [20]. We compared
the baseline clinical characteristics and prognoses of the
two groups, and found no significant difference in clin-
ical characteristics or survival time after the diagnosis of
an uncommon metastasis between the groups. It is pos-
sible that the patients in different groups represent dif-
ferent courses of the disease. Nonetheless, we couldn’t
have a definitive explanation for this phenomenon with-
out complete data for further analysis.
Uncommon metastases usually occur in patients with
other disseminated metastases. Traditionally, systemic
therapy is recommended as the standard therapy for
metastatic disease. We administered local treatment in
addition to systemic treatment to selected patients with
oligometastases. More cases in the disease course group
received local treatment. The patients who received sys-
temic treatment plus local treatment had a better outcome
than those who did not. Similar results have been ob-
served in other studies [21, 22]. Therefore, we advise sys-
temic treatment plus local treatment for selected patients
with oligometastases.
A limitation of our study is its retrospective design,
which spanned a long period of time. Regardless, it is
the largest case series of uncommon metastases derived
from NSCLC to date, and may aid clinicians in their
treatment efforts.
Conclusions
In conclusion, uncommon metastases are infrequently
and associated with a worse outcome. Systemic treat-
ment plus local treatment is a favorable option for se-
lected patients with oligometastases.
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